Literature DB >> 27167732

A case highly suspicious of isolated cardiac sarcoidosis.

M P Huitema1, M J Swaans2, J C Grutters3, M C Post2.   

Abstract

Entities:  

Year:  2016        PMID: 27167732      PMCID: PMC4887304          DOI: 10.1007/s12471-016-0837-3

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


× No keyword cloud information.
A 55-year-old Caucasian male without cardiac history presented with a broad-complex tachycardia of a right ventricular origin (Fig. 1a). After successful electrocardioversion, echocardiography and coronary angiogram showed no significant abnormalities. Electrophysiological examination suggested a right ventricular mid-septal origin of the arrythmia, closely to the HIS bundle. Cardiac MRI (Fig. 1b,c) showed extensive late enhancement at the right ventricular part of the interventricular septum (Fig. 1b) and a focal lesion in the epicardial inferolateral wall (Fig. 1c), both showing high uptake on FDG PET-CT (Fig. 1d). In the laboratory findings, soluble interleukin-2 receptor (sIL-2R), a marker for sarcoidosis, was elevated (5276 pg/ml, normal value <3000 pg/ml), making cardiac sarcoidosis highly likely. FDG PET-CT and examination of skin and eyes showed no signs of extracardiac sarcoidosis and pulmonary sarcoidosis was excluded by high-resolution CT and bronchoalveolar lavage, suggesting a case of isolated cardiac sarcoidosis. The prevalence of cardiac involvement in sarcoidosis varies from 5 % in symptomatic patients to up to 30 % in autopsies [1]. Isolated cardiac sarcoidosis is rare and only described in case series [2]. For diagnosis, multimodality imaging is recommended, including MRI and FDG PET [3]. FDG PET is the modality of choice to examine (extra)cardiac sarcoidosis [4]. Giant cell myocarditis can be considered in the differential diagnosis. However the scan results, elevated sIL-2R, young age and dysrhythmia are typical for cardiac sarcoidosis. A two-chamber implantable cardioverter defibrillator was implanted and prednisolone treatment was started. FDG PET-CT after 3 months showed complete normalisation. Although extremely rare, this case illustrates the possible occurrence of mono-organ localisation of sarcoidosis.
Fig. 1

a Electrocardiogram showing a broad-complex tachycardia of 240 beats/min, retrograde P waves and right-axis deviation, suggesting a right ventricular origin. Cardiac MRI shows extensive late enhancement at the right ventricular part of the interventricular septum (arrow in b1 and b2), and a focal lesion in the epicardial inferolateral wall (arrow in c). d FDG PET-CT shows a high uptake lesion of the inferolateral wall (arrow), correlating with MRI

a Electrocardiogram showing a broad-complex tachycardia of 240 beats/min, retrograde P waves and right-axis deviation, suggesting a right ventricular origin. Cardiac MRI shows extensive late enhancement at the right ventricular part of the interventricular septum (arrow in b1 and b2), and a focal lesion in the epicardial inferolateral wall (arrow in c). d FDG PET-CT shows a high uptake lesion of the inferolateral wall (arrow), correlating with MRI
  4 in total

1.  The invisible made visible: multi-modality imaging in the evaluation of cardiac sarcoidosis.

Authors:  Emer Joyce; Victoria Delgado; Maarten K Ninaber; Nina Ajmone Marsan
Journal:  Eur Heart J       Date:  2013-02-07       Impact factor: 29.983

2.  Isolated right ventricular cardiac sarcoidosis demonstrated by ¹⁸FDG positron emission tomography.

Authors:  Miguel Hernandez Pampaloni; Babek Nazer; Babek Nazar; Elias Botvinick
Journal:  J Nucl Cardiol       Date:  2014-01-16       Impact factor: 5.952

Review 3.  Cardiac sarcoidosis: Case-studies and a brief review of the literature.

Authors:  J P Smedema; P E Zondervan; P van Hagen; F J Ten Cate; P Bresser; A F Doubell; P Pattynama; H C Hoogsteden; A H M M Balk
Journal:  Neth Heart J       Date:  2002-08       Impact factor: 2.380

4.  FDG PET for gauging of sarcoid disease activity.

Authors:  Human Adams; Ruth G Keijsers; Ingrid H E Korenromp; Jan C Grutters
Journal:  Semin Respir Crit Care Med       Date:  2014-07-09       Impact factor: 3.119

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.